Getting a new drug, biologic, or medical device to market is not a quick process. One of the biggest questions sponsors ask is simple: how long will this take? The answer depends on many factors, but understanding the key milestones can help you plan better and avoid surprises.
In this blog, we have broken down what happens at each stage of a regulatory submission, so you know what to expect and when.
Why Timelines Matter
A clear timeline helps your team plan resources, budgets, and launch dates. It also helps you communicate realistic expectations to leadership and investors. Without this clarity, delays can catch teams off guard and push back product launches by months or even years.
Several things affect how long a submission takes:
- The type of product (drug, biologic, or device)
- The regulatory pathway chosen (standard or expedited)
- The country or region where you are filing
- The quality and completeness of your data
Data quality becomes particularly important as sponsors move toward submission. Specialist clinical data management helps ensure that clinical data is collected, reviewed, cleaned and prepared consistently before it feeds into regulatory documentation.
Milestone 1: Pre-Submission Planning
Before you file anything, there is a planning phase. This is where sponsors meet with regulators to align on expectations. Common activities include:
- Pre-IND or pre-submission meetings with agencies
- Finalising nonclinical and clinical study data
- Internal quality checks on all data and reports
This phase can take several months to over a year, depending on how much data still needs to be collected or reviewed.
Milestone 2: Preparing the Dossier
Once your data is ready, the next step is compiling the full regulatory submission. This involves pulling together every required document into the correct format, usually the Common Technical Document (CTD) or electronic CTD (eCTD).
This stage needs close teamwork between:
- Regulatory affairs
- Clinical teams
- Chemistry, manufacturing, and controls (CMC) experts
- Medical writers
Good coordination here can save weeks of rework later. Many sponsors choose to work with outside regulatory submission services to manage this complex process, especially when filing in multiple countries at once.
Milestone 3: Filing and Initial Review
Once the dossier is complete, it goes to the agency. The first thing that happens is not a full review. It is a completeness check.
| Agency | Initial Check Name | Typical Timeframe |
| FDA (US) | Filing review (Refuse to File decision) | About 60 days |
| EMA (Europe) | Validation | About 1 to 2 weeks |
| PMDA (Japan) | Formal review | About 1 month |
Many submission problems are preventable. Understanding why regulatory submissions fail can help sponsors identify documentation, consistency and compliance issues before filing. This is why complete and accurate regulatory submission documents matter so much.
Milestone 4: Substantive Review
This is the main review period, where the agency studies your data in detail. Timelines vary a lot here:
- Standard review can take 10 to 12 months (FDA) or similar timeframes at other agencies
- Priority or expedited pathways can cut this down to 6 to 8 months
- The agency may pause the clock to ask for more information, which extends the timeline
During this phase, agencies may also schedule advisory committee meetings for complex or novel products. How fast your team responds to information requests directly affects how long this stage takes.
Milestone 5: The Decision
At the end of the review, there are usually three possible outcomes:
- Approval: Meaning the product can move toward market
- A request for more information: This is often called a Complete Response Letter in the US
- Rejection: Usually means major issues with safety, efficacy, or data quality
The time from submission to decision varies by product type, but most sponsors should plan for 10 months to 2 years for a full cycle, factoring in review, questions, and responses.
Milestone 6: After the Decision
Approval is not always the finish line. There is often more to do:
- Negotiating final product labelling
- Meeting post-marketing study commitments
- Planning launch sequencing across different regions
Tips for Managing Expectations
A few simple practices can make a big difference:
- Build in buffer time for unexpected delays or information requests
- Keep documentation organised and complete from the start
- Set up a clear internal regulatory affairs submission process so everyone knows their role and deadlines
- Communicate timeline updates to stakeholders regularly, not just at major milestones
Because the dossier depends on consistent, submission-ready documentation, sponsors may also use specialist medical writing services to prepare and review key regulatory documents.
Best Regulatory Service in India
Bringing a new product from lab development to market approval is a long and costly process. Regulatory delays can add significant time and expense for innovators. Innovate Research provides regulatory consulting services in India for pharmaceutical, biotechnology, API manufacturing, finished formulations, medical device, and food and beverage companies.
Innovate Research provides seamless, transparent, and up to date regulatory consulting services to clients in Pharmaceuticals, Biotechnology, API manufacturing, Finished Formulations, Medical Devices, and Food and Beverage.
Our approach is simple. We study each client’s needs in depth, then plan ahead and execute regulatory filings with precision, in full compliance with relevant agencies. This lets us deliver global regulatory support, well ahead of schedule.
Final Thoughts
Every regulatory submission moves through a series of predictable milestones, even though the exact timing can shift based on product type, region, and how quickly questions get resolved. Knowing what to expect at each stage helps teams plan smarter, avoid last minute scrambles, and keep everyone aligned on realistic timelines.
Planning ahead, staying organised, and working closely with regulatory experts are the best ways to keep your submission on track from start to finish.
Along with regulatory submissions, we also provide services like clinical trail, clinical site management, biostatics services, biospecimen collection, and more. Visit Innovate Research to learn more about our services.
FAQs
- What factors can delay a regulatory submission timeline?
Delays can result from incomplete documentation, additional agency questions, manufacturing concerns, missing clinical data, formatting issues, or slow responses to regulatory requests.
- Can regulatory submission timelines differ for drugs, biologics, and medical devices?
Yes. Each product type follows different regulatory pathways and review requirements, so submission and approval timelines can vary significantly.
- What is the difference between standard andexpeditedregulatory review?
Standard review follows the normal agency timeline, while expedited pathways may shorten the review period for eligible products addressing serious or unmet medical needs.
- How can companies reduce delays during regulatory review?
Companies can reduce delays by preparing complete documentation, conducting thorough quality checks, responding quickly to agency questions, and maintaining clear communication between regulatory, clinical, CMC, and medical writing teams.
- Why do companies use regulatory submission services?
Regulatory submission services can help sponsors manage dossier preparation, document quality, eCTD publishing, agency requirements, and multi-country submissions while keeping the process organised and compliant.